52 results about "Cross immunity" patented technology

The invention relates to a recombinant avian influenza virus strain. The recombinant avian influenza virus strain is obtained by recombination construction of an influenza virus strain and an avian influenza virus strain through a genetic recombination method, has no pathogenicity to chickens and chicken embryos, is safer than wild strains, and can effectively avoid divergence risk caused by incomplete inactivation. The invention also relates to a newcastle disease, infectious bronchitis and H9 subtype avian influenza resisting vaccine composition containing the recombinant avian influenza virus strain. The vaccine composition not only can prevent newcastle disease and infectious bronchitis, but also has good cross immunity to most H9N2 subtype avian influenza viruses currently prevalent in China. Therefore, compared with current commercial vaccines, the vaccine composition has wide cross protection in terms of H9N2 subtype avian influenza.

The invention discloses a broad-spectrum vibrio subunit vaccine for preventing fish pathogenic vibrio infection and a preparation method, belonging to the technical field of biology. The fusion protein OmpK-FlaA of an outer membrane protein OmpK with a conserved structure and a flagellin protein FlaA on the vibrio parahaemolyticus surface serves as an antigen component of the vaccine. The method is characterized by comprising the following steps of: superposing and extending Ppolymerase chain reaction (PCR) to the ompK and flaA genes of the vibrio parahaemolyticus to obtain a fusion protein gene flaA-ompK; constructing flaA-ompK-pET-28a recombinant plasmids; and obtaining the fusion FlaA-OmpK with high purity through exogenous induction expression and purification. The vaccine prepared bythe invention is safe and nontoxic and has no side effects; injection immune can be adopted; and the immune can also be realized by taking enteric microsphere vaccine orally; cross immunity protection can be acted to fish pathogenic vibrio (vibrio parahaemolyticus, vibrio alginolyticus, vibro harveyi, vibrio anguillarum and vibrio vulnificus).

The invention discloses an application of an electrochemical immunosensor in the aspect of multi-residue detection of sulfonamides. According to the application, firstly, the surface of a glassy carbon electrode is modified with polysulfadiazine with an in-situ electrochemical polymerization method, secondly, detection for four sulfonamides including sulfadiazine, sulfamethazine, sulfacetamide andsulfaguanidine is realized on the basis of cross-immune response of sulfadiazine antibodies and sulfonamides, wherein the limit of detection is in a range of 0.06-0.15 ng / mL, and linear range is 0.1-1500 ng / mL or 0.3-500 ng / mL.

The invention relates to preparation and application of a multi-epitope vaccine with cross immunity protective efficiency to O-type foot-and-mouth disease viruses such as OZK / 93, OR / 80MF8, OS / 99MF8, OHK93 and the like. The vaccine contains two sections of T cell auxiliary antigenic epitope polypeptides, 4-7 sections of antigenic epitope polypeptides related to main outer membrane proteins VP1, VP2 and VP3 of different foot-and-mount disease strains. The invention also relates to a preparation method of the vaccine and a clinical immunology application method. The vaccine has stable production preparation process and is applicable to mass production, experiments show that the multi-epitope vaccine is safe to use, infection of different O-type foot-and-mouth circulating strains can be effectively prevented and effective antibody titer can last for at least seven months.

The invention discloses an influenza vaccine and a preparation method based on self-assembled ferritin nanometer antigen particles. In the present invention, the extracellular domain of the influenza virus hemagglutinin protein is fused and expressed with the N-terminal of the self-assembled ferritin nanoparticle subunit, and the influenza virus hemagglutinin protein is displayed on the surface of the self-assembled ferritin cage structure. The invention carries out mutation optimization of the influenza virus hemagglutinin protein, improves its soluble expression amount and expression efficiency, improves the immune efficacy and breadth of the vaccine, and improves the immunogenicity of the influenza virus hemagglutinin protein. The present invention utilizes E. coli prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express and prepare recombinant protein vaccine respectively, or generate antigen and induce antibody production by gene presentation of recombinant baculovirus in vertebrate in vivo tissue. The influenza vaccine of the invention can induce broadly neutralizing anti-influenza antibodies, can not only improve the immune efficacy but also expand the immune range, and has the potential of a universal vaccine with cross-immunity efficacy.

The invention relates to biological immunity and a vaccine, and in particular discloses a coccidiosis vaccine component having a cross immunological protection capacity and a vaccine containing the coccidiosis vaccine component. The coccidiosis vaccine component is a transgenic coccidiosis strain capable of expressing heterogeneous coccidiosis immunity dominant antigens. The transgenic coccidiosis strain, which simultaneously has immunogenicities of a parental coccidiosis strain and a heterogeneous coccidiosis strain, can enhance the cross immunological protection capacity of the coccidiosis vaccine component when the transgenic coccidiosis strain serves as the coccidiosis vaccine component. Based upon experimental studies, it discovers that the cross immunological protection capacity, which is provided by the novel vaccine component, is positively correlated to the quantity of the expressed heterogeneous dominant antigens; therefore, preferably, a plurality of immunity dominant antigens are expressed. According to the coccidiosis vaccine component and a construction strategy thereof provided by the invention, the immunological protection capacity can be offered for various insect infections; and the cross immunological protection capacity is universal.

The invention discloses a rabies vaccine and application based on self-assembled ferritin nanometer antigen particles and prepared therefrom. In the invention, the rabies virus G antigen protein is fused with the self-assembled ferritin nanoparticle subunit to obtain a fusion protein. In the present invention, the rabies virus G antigen protein is subjected to site mutation, and the soluble expression amount and expression efficiency of the obtained mutant are significantly improved. The present invention utilizes prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express recombinant protein, or performs gene presentation in vertebrate body by recombinant baculovirus to produce antigen and induce antibody production. The rabies vaccine provided by the present invention displays antigenic proteins on the surface of the ferritin cage structure of Helicobacter pylori, causing broadly neutralizing anti-rabies virus antibodies, improving immune efficacy and expanding the scope of immunity, and has the potential of a universal vaccine with cross-immunity efficacy . The vaccine preparation method of the present invention is safe and convenient, and is suitable for rapid large-scale production.

The invention belongs to the field of biological medicines, and relates to a mutant protein vaccine aiming at tumor necrosis factor alpha (TNF-alpha) and applications of the mutant protein vaccine. The invention aims at providing the protein vaccine which is good in property and takes TNF-alpha as the target spot. According to the scheme, by immunizing the TNF-alpha mutant protein vaccine, the biological activity of the TNF-alpha mutant protein vaccine is inhibited, the cross immunologic reaction is generated in vivo, the biological functions of TNF-alpha are neutralized, and the autoimmune diseases and inflammatory diseases are inhibited. The protein vaccine aiming at TNF-alpha can be used for treating the autoimmune diseases and the inflammatory diseases and preventing the relapse of the autoimmune diseases and the inflammatory diseases.

The invention relates to the field of immunology, specifically to a weak poisonous fluorescent pseudomonas and immune application method thereof. Specifically, the weak poisonous fluorescent pseudomonas has cross immunity protective effect to the hydrosphere unit cell bacterium, Ludwik Yersinia and fluorescent pseudomonas; the immune application method includes an injection method and an immersion method, wherein the injection method is directly performing abdominal cavity injection the weak poisonous fluorescent pseudomonas cultured in the LB substrate into the fishes, and the immersion method is soaking the fishes in the vaccine soak containing the weak poisonous fluorescent pseudomonas for a certain period of time. The vaccine obtained by the invention not only has efficient cross-protection effect at the same time to the three different types of pathogenic bacteria, and but also has a simple preparation and immunization operation without any purification process.

The invention discloses a sarcocystis fusion antigen, coding gene, indirect ELISA antibody detection kit and application thereof, belonging to the technical field of animal or human disease detection. The sarcocystis fusion antigen of the present invention consists of the partial amino acid sequence (37-118) of the surface antigen SAG3 of Sarcocystis mieni, a flexible peptide of 15 amino acids and the partial amino acid sequence of the surface antigen SAG4 of Sarcocystis cruzi (No. 165‑264) constitutes; this fusion antigen has very strong antigenicity and specificity, can produce effective antigen antibody reaction with S. The positive sera of Toxoplasma gondii and Neospora caninum produce cross-immune reactions, which are ideal detection antigens for detecting antibodies against Sarcocystis micheni and Sarcospora cruzi, and have a good application prospect.